A Retrospective Study on the Effectiveness of Ixekizumab After Treatment With Secukinumab for Patients With Active Psoriatic Arthritis

Objectives: This study aims to evaluate clinical responses in patients with active psoriatic arthritis who, despite secukinumab 300 mg subcutaneous monthly, are switched ixekizumab 80 every four weeks. Methods: We conducted a chart review of adult treated at one center. identified all inflammatory who were from ixekizumab. Baseline demographics such as disease duration, age, gender, number previous DMARDs, and time on collected. collected outcome data tender swollen joint count, enthesitis based SPARCC score, dactylitis, psoriasis severity, CRP, BASDAI if axial involvement was present. Results: Eight 10 included the analysis. Most female, average age 62 years old, had been for an 79 Twelve weeks following switch ixekizumab, 6/8 improvement improved 2/2 resolution enthesitis, 4/4 5/6 1 patient absolute 2.3 BASDAI, 7/8 CRP level. Conclusions: Patients treatment may still have response another anti-IL17 agent. Larger studies will be required confirm this finding, which emphasize dactylitis outcomes needed most did not activity these domains.